Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 7/20 | 0.39 |
| ▸ | AAK1 | Q2M2I8 | 4/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | MPO | P05164 | 6/20 | 0.34 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.33 |
| ▸ | FEN1 | P39748 | 1/20 | 0.33 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3755716 | 0.83 | NOS1 (0.40) | NOS1MPOALOX5APFEN1PIK3CG | |
| SCHEMBL3762597 | 0.82 | NOS1 (0.37) | NOS1HPGDSMN1; SMN2MPOPIK3CG | |
| SCHEMBL3757250 | 0.82 | NOS1 (0.42) | NOS1KDM4EMPOPIK3CG | |
| SCHEMBL3760895 | 0.81 | MPO (0.40) | NOS1KDM4EMPOPIK3CG | |
| SCHEMBL3767203 | 0.81 | NOS1 (0.38) | NOS1KDM4EHPGDSMN1; SMN2MPO | |
| SCHEMBL3759373 | 0.80 | NOS1 (0.40) | NOS1MPOALOX5APPIK3CG | |
| SCHEMBL3752631 | 0.79 | NOS1 (0.43) | NOS1KDM4EMPOALOX5APFEN1 | |
| SCHEMBL3760969 | 0.79 | L3MBTL1 (0.47) | NOS1MPO | |
| SCHEMBL3765405 | 0.78 | ROCK2 (0.39) | NOS1MPOPIK3CG | |
| SCHEMBL3757233 | 0.78 | MAPT (0.48) | NOS1KDM4EMPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190152974-A1 | SUBSTITUTED PTERIDINES USEFUL FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2019-05-23 | — | — | US | claimed |
| US-20100305117-A1 | SUBSTITUTED PTERIDINES USEFUL FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2010-12-02 | — | — | US | claimed |
| WO-2008009079-A2 | SUBSTITUTED PTERIDINES USEFUL FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2008-01-24 | — | — | WO | claimed |
| US-20190152974-A1 | SUBSTITUTED PTERIDINES USEFUL FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2019-05-23 | — | — | US | disclosed |
| US-10144736-B2 | Substituted pteridines useful for the treatment and prevention of viral infections | GILEAD SCIENCES, INC. (US) | 2018-12-04 | — | — | US | disclosed |
| US-20100305117-A1 | SUBSTITUTED PTERIDINES USEFUL FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| WO-2008009079-A2 | SUBSTITUTED PTERIDINES USEFUL FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190152974-A1 | SUBSTITUTED PTERIDINES USEFUL FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTIONS | HCCS, DPYD, HAVCR2 | NOS1 2154/4885AAK1 3356/4885KDM4E 763/4885 |
| US-10144736-B2 | Substituted pteridines useful for the treatment and prevention of viral infections | HCCS, DPYD, HAVCR2 | NOS1 2154/4885AAK1 3356/4885KDM4E 763/4885 |
| US-20100305117-A1 | SUBSTITUTED PTERIDINES USEFUL FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTIONS | HCCS, DPYD, HAVCR2 | NOS1 2154/4885AAK1 3356/4885KDM4E 763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.